Last updated: October 1, 2023
Sponsor: National Cheng-Kung University Hospital
Overall Status: Active - Enrolling
Phase
N/A
Condition
Connective Tissue Diseases
Heartburn
Gastrointestinal Diseases And Disorders
Treatment
Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains
The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)
Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains
Clinical Study ID
NCT05238181
B-ER-110-440
Ages 20-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who present with relevant symptoms or signs of upper gastrointestinaldiseases, including, but not limited to the following: impaired gastric emptying,epigastric discomfort, postprandial bloating, early satiety, epigastric pain, acidregurgitation, dyspepsia, anemia, or vitamin B12 deficiency, or iron deficiency, arecandidates to be enrolled to receive gastroscopy.
Exclusion
Exclusion Criteria:
- The exclusion criteria are as follows including use of aspirin, non-steroidalanti-inflammatory drugs, or cyclooxygenase-2 selective inhibitors for more than 3months, or diagnosis with upper gastrointestinal cancer including esophagus, stomach,duodenum, mucosa-associated lymphoid tissue lymphoma, other gastric lymphoma, orpancreas.
Study Design
Total Participants: 300
Treatment Group(s): 3
Primary Treatment: Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains
Phase:
Study Start date:
January 01, 2022
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
National Cheng Kung University Hospital
Tainan, 704302
TaiwanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.